The introduction of highly active antiretroviral therapy (HAART) has dramatically reduced mortality from HIV infection. However, several studies have suggested an association between protease inhibitors (PIs), which are integral components of most HAART regimens, and metabolic disturbances (mainly dyslipidaemia) that may increase atherosclerotic burden and the risk of cardiovascular events. There is a number of strategies for managing HAART-related dyslipidaemia, and their advantages and disadvantages should be considered when treating HIV infected patients. In this review, we summarize current knowledge of cardiovascular prevention in these conditions, with emphasis on controlling hypertriglyceridaemia.
|Translated title of the contribution||Metabolic alterations and therapeutic approach in patients with HAART therapy|
|Number of pages||10|
|Journal||Trends in Medicine|
|Publication status||Published - Apr 2007|
ASJC Scopus subject areas
- Internal Medicine
- Pharmacology (medical)